首页> 外文期刊>Toxicon: An International Journal Devoted to the Exchange of Knowledge on the Poisons Derived from Animals, Plants and Microorganisms >ImKTx88, a novel selective Kv1.3 channel blocker derived from the scorpion Isometrus maculates
【24h】

ImKTx88, a novel selective Kv1.3 channel blocker derived from the scorpion Isometrus maculates

机译:ImKTx88,一种源自蝎Isometrus maculatus的新型选择性Kv1.3通道阻滞剂

获取原文
获取原文并翻译 | 示例
           

摘要

Scorpion toxins are useful in the structure-function research of ion channels and valuable resources for drug design. The Kv1.3 channel is an important pharmacological target for the therapy of T cell-mediated autoimmune diseases, and many toxin peptides targeting Kv1.3 have been identified as good drug candidates in recent years. In this study, a novel toxin gene ImKTx88 was isolated from the venom of the scorpion Isometrus maculates through the construction of the cDNA library method, and the recombinant toxin peptide was purified and characterized physiologically. The mature peptide of ImKTx88 contained 39 amino acid residues including six cysteines and was predicted to be a new member of alpha -KTx scorpion family by sequence analysis. The electrophysiological experiments further indicated that the rImKTx88 peptide had a novel pharmacological profile: it inhibited Kv1.3 channel current with an IC50 of 91aaA plus or minus aa42pM, and exhibited very good selectivity for Kv1.3 over Kv1.1 (4200-fold) and Kv1.2 (93000-fold) channels, respectively. All these results suggested that, as a new selective Kv1.3 channel blocker, the ImKTx88 peptide may serve as a potential drug candidate in the therapy of autoimmune diseases.
机译:蝎毒素可用于离子通道的结构功能研究和药物设计的宝贵资源。 Kv1.3通道是治疗T细胞介导的自身免疫性疾病的重要药理学靶标,近年来,许多靶向Kv1.3的毒素肽被确定为良好的候选药物。在这项研究中,通过构建cDNA文库方法,从蝎Isometrus的毒液中分离出了新的毒素基因ImKTx88,并纯化了重组毒素肽并对其进行了生理学表征。 ImKTx88的成熟肽含有39个氨基酸残基,其中包括6个半胱氨酸,通过序列分析可以预测它是α-KTx蝎子家族的新成员。电生理实验进一步表明,rImKTx88肽具有新颖的药理作用:它抑制Kv1.3通道电流,IC50为91aaA正负aa42pM,并且对Kv1.3的选择性优于Kv1.1(4200倍)和Kv1.2(93000倍)频道。所有这些结果表明,作为一种新的选择性Kv1.3通道阻滞剂,ImKTx88肽可作为自身免疫性疾病治疗的潜在候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号